Patients who were treated with sulfonylureas and insulin were more likely to experience severe hypoglycemia, whereas patients who were treated with sodium-glucose cotransporter 2 inhibitors and those requiring insulin therapy were more likely to experience DKA or HHS. The gene discussed is SLC5A2; the disease is Hypoglycemia.